NCT07088068 - A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Biotech Hunter

Enrollment

723

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

June 6, 2028

Study Completion Date

December 12, 2028

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

Teplizumab

Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

OTHER

Placebo

Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

Trial Locations (11)

28803

RECRUITING

Asheville Clinical Research- Site Number : 8400045, Asheville

30281

RECRUITING

Atlanta Institute of Endocrinology- Site Number : 8400050, Stockbridge

30318

RECRUITING

Atlanta Diabetes Associates- Site Number : 8400036, Atlanta

31904

RECRUITING

Centricity Research- Site Number : 8400003, Columbus

38133

RECRUITING

AM Diabetes & Endocrinology Center- Site Number : 8400004, Bartlett

55905

RECRUITING

Mayo Clinic- Site Number : 8400019, Rochester

83404

RECRUITING

Rocky Mountain Clinical Research, LLC- Site Number : 8400001, Idaho Falls

85260

RECRUITING

Scottsdale Clinical Trials- Site Number : 8400044, Scottsdale

92647

RECRUITING

Marvel Clinical Research- Site Number : 8400042, Huntington Beach

98101-2795

RECRUITING

Benaroya Research Institute at Virginia Mason- Site Number : 8400038, Seattle

DD1 9SY

RECRUITING

Investigational Site Number : 8260004, Dundee